Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other current liabilities remains negative

Q2 FY2026 other current liabilities was $0, compared with $75.53M a year earlier. Over 3 fiscal years it compounded at +101.0% a year.

Context

  • Other current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 21.4 pp from a year earlier.
  • Other current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$116.31M+460.6% YoY
Year agoJun 2025
$75.53M-100.0% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+460.6%——
3-year CAGR+101.0%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
116.31M USD
Year-over-year change
+460.6%
4-year CAGR
+63.2%

Other Current Liabilities vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's Jun 2026 other current liabilities of $0 is the 5th highest of the 6 companies compared; the peer median is $1.32M.
  • Its year-over-year change of -100.0% is the lowest of 4, against a peer median of -69.0%.
  • Other current liabilities amounts to 0.0% of total assets for ARQT, versus a peer median of 2.0%.
ARQT Competitors Peer median
Other Current Liabilities for ARQT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACRSAclaris Therapeutics, Inc.Mar 2026$6.06M -39.9%-8.8%3.0%
TTRXTurn Therapeutics Inc.Mar 2026$2.77M ——14.8%
ALDXAldeyra Therapeutics, Inc.Mar 2026$1.32M -69.0%+3.8%2.0%
EVMNEvommune, Inc.Mar 2026$1.3M -89.7%—0.4%
ARQTArcutis Biotherapeutics, Inc.Jun 2026$0 -100.0%+101.0%0.0%
SLGLSol-Gel Technologies Ltd.Mar 2026$0 ——0.0%
Peer median (excluding ARQT) $1.32M-69.0%-2.5%2.0%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents97.99M53.64M88.4M71.34M42.91M
Short-term Investments290.61M355.95M183.46M156.62M178.08M
Net Receivables362K8.46M25.81M73.07M146.23M
Inventory07.51M13.13M14.53M22.63M
Other Current Assets7.66M4.46M9.53M8.82M9.79M
Total Current Assets402.77M437.41M330.43M335.82M411.23M
Property, Plant & Equipment (Net)5.3M4.6M3.9M2.99M5.51M
Goodwill00000
Intangible Assets07.19M6.44M9.48M14.81M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets78K78K596K596K1.42M
Total Non-current Assets5.38M11.87M10.93M13.07M21.74M
Total Assets408.15M449.27M341.37M348.89M432.97M
Account Payables7.35M8.83M11.99M14.22M12.53M
Short-term Debt433K0001M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities16.41M14.32M19.07M20.75M116.31M
Total Current Liabilities33.33M37.81M46.67M81.01M129.84M
Long-term Debt72.35M197.77M201.8M107.2M5.27M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities25K0849K570K108.39M
Total Non-current Liabilities77.15M201.89M206.03M110.34M113.66M
Total Liabilities110.48M239.69M252.7M191.35M243.49M
Common Stock5K6K9K12K12K
Retained Earnings(408.31M)(719.76M)(981.9M)(1.12B)(1.14B)
Accumulated OCI(255K)(1.09M)4K(7K)(44K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity297.68M209.58M88.67M157.54M189.48M
Total Debt77.56M202.54M205.92M110.59M6.27M
Net Debt(20.43M)148.9M117.52M39.25M(36.64M)

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.